| Identification | Back Directory | [Name]
Larazotide | [CAS]
258818-34-7 | [Synonyms]
AT2347
AT-2347
AT 2347
larazotide
Unii-zn3R5560zv
Gly-Gly-Val-Leu-Val-Gln-Pro-Gly
Glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolylglycine
Glycine, glycylglycyl-L-valyl-L-leucyl-L-valyl-L-glutaminyl-L-prolyl- | [Molecular Formula]
C32H55N9O10 | [MDL Number]
MFCD13194765 | [MOL File]
258818-34-7.mol | [Molecular Weight]
725.83 |
| Chemical Properties | Back Directory | [density ]
1.254 | [storage temp. ]
Store at -20°C | [solubility ]
DMSO: Insoluble;Ethanol: Insoluble | [form ]
Solid | [color ]
White to off-white | [Water Solubility ]
Water: 25 mg/mL (34.44 mM) | [Sequence]
H-Gly-Gly-Val-Leu-Val-Gln-Pro-Gly-OH |
| Hazard Information | Back Directory | [Uses]
Larazotideis a peptide which is an orally active zonulin antagonist. Larazotide shows antiviral activity to varicella-zoster virus (VZV) with EC50s of 44.14 and 59.06 μM for strain OKA and 07-1, respectively. Larazotide can be used for the research of celiac disease and infection[1][2]. | [Definition]
ChEBI: Larazotide is an oligopeptide. | [in vivo]
Larazotide (250 μg; i.p. twice a week for 7 weeks) inhibits intestinal permeability in gluten-sensitive transgenic mice[1]. | Animal Model: | HLA-HCD4/DQ8 double transgenic mice[2] | | Dosage: | 250 μg | | Administration: | Intraperitoneal injection; 250 μg twice a week for 7 weeks | | Result: | Improved barrier function parameters and reduced macrophage counts in the lamina propria to control levels.
|
| [References]
[1] Di Micco S, et al. Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation. Int J Mol Sci. 2021 Aug 30;22(17):9427. DOI:10.3390/ijms22179427
[2] Gopalakrishnan S, et al. Larazotide acetate regulates epithelial tight junctions in vitro and in vivo. Peptides. 2012 May;35(1):86-94. DOI:10.1016/j.peptides.2012.02.015 |
|
|